---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024365"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-05-19T13:00:16+00:00"
generated_at: "2026-05-19T13:09:13.772674+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine LPCN 1154 Phase 3 data accepted for oral presentation at 2026 ASCP meeting

## Summary
- Phase 3 data for LPCN 1154 (oral brexanolone) for postpartum depression accepted for oral and poster presentation at ASCP Annual Meeting May 26-29, 2026 in Miami, FL.
- Oral presentation by Benjamin Bruno, PhD, VP Clinical Development, on May 26, 2026 at 3:20 PM ET; poster session on May 27.
- LPCN 1154 is an oral non-SSRI neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors.
- Potential for acute stabilization of PPD symptoms with low CNS depressant side effects, no intensive monitoring required.

## SEC filing metadata
- accession: 0001493152-26-024365
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-05-19T13:00:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226024365/0001493152-26-024365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226024365/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024365
- JSON: https://secwatch.observer/filing/0001493152-26-024365.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024365.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.